Loading
A phase 3 trial of Capivasertib, Docetaxel in prostate cancer, run by AstraZeneca, active and no longer recruiting.
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC) is a phase 3 interventional study registered as NCT05348577 by AstraZeneca, with 1035 participants enrolled, started 2022-03-25 and due to reach its primary completion in 2026-03-04. Interventions recorded: capivasertib, docetaxel, placebo. Conditions listed: Prostate Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PI3K, AKT and mTOR inhibitors, Capivasertib, AstraZeneca, Small-molecule kinase inhibitors.
Shares PI3K, AKT and mTOR inhibitors, Capivasertib, AstraZeneca, Small-molecule kinase inhibitors.
Shares PI3K, AKT and mTOR inhibitors, Docetaxel, Metastatic castration-resistant prostate cancer, Small-molecule kinase inhibitors.
Shares Docetaxel, Metastatic castration-resistant prostate cancer, Cytotoxic chemotherapy, Prostate cancer.
Shares PI3K, AKT and mTOR inhibitors, Capivasertib, AstraZeneca, Small-molecule kinase inhibitors.
Shares PI3K, AKT and mTOR inhibitors, Capivasertib, AstraZeneca, Small-molecule kinase inhibitors.
Shares Metastatic castration-resistant prostate cancer, AstraZeneca, Prostate cancer.
Shares Docetaxel, Metastatic castration-resistant prostate cancer, Cytotoxic chemotherapy, Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/